• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer

  2026-09-01

  A 2026 FASEB Journal study developed chemically modified p21 mRNA–loaded lipid nanoparticles for localized intravesical treatment of bladder cancer. The work links restoration of nuclear p21 to cell-cycle suppression, DNA-damage signaling, apoptosis, and tumor control in an orthotopic mouse model, while showing limited systemic distribution.

• Coumestrol, PMAIP1, and Ferroptosis in RA-FLS

  2026-08-31

  The reference study identifies a mechanistic link between Coumestrol treatment, TRIM3-dependent stabilization of mitochondrial PMAIP1, and ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. Its integrated phenotype and knockdown experiments suggest a useful framework for studying synoviocyte proliferation and inflammation, while the in vitro design limits direct therapeutic interpretation.

• TLS, TRAF2 Competition, and B-Cell Activation in ESCC

  2026-08-31

  A 2025 Cancer Gene Therapy study identifies tertiary lymphoid structures as an independent favorable prognostic feature in treatment-naïve esophageal squamous cell carcinoma and defines an IRF4-centered mechanism of B-cell activation. Its central mechanistic insight is that CD40 and STING compete for TRAF2, linking receptor signaling, STING ubiquitination and phosphorylation, non-canonical NF-κB activity, and TLS-associated immunity.

• AMG 9810: TRPV1 Antagonism Under Stress

  2026-08-30

  AMG 9810 is a selective TRPV1 antagonist for separating sensory calcium signaling from metabolic-stress adaptation. This article connects rigorous TRPV1 assay design with the AMPK–SQSTM1/NRF2 findings of a 2024 autophagy study while clearly defining the evidence limits.

• Human iPSC Hepatobiliary Organoids: Study Insights

  2026-08-29

  Wu et al. established a three-stage method for generating three-dimensional hepatobiliary organoids from human induced pluripotent stem cells without exogenous cells or genetic manipulation. The resulting structures combined hepatocyte-like and biliary functions, providing a platform for studying liver development, drug metabolism, and liver disease modeling.

• CHK1 Inhibition in ER/PR-Stratified Breast Cancer

  2026-08-28

  The reference study demonstrates that CHK1 inhibition has subtype-dependent effects in breast cancer: it enhances adriamycin sensitivity in ER−/PR−/HER2− disease but shows single-agent activity rather than chemosensitization in ER+/PR+/HER2− models. Its integrated database, drug-response, cell-cycle, apoptosis, and transcriptome analyses provide a framework for matching CHK1-targeted strategies to receptor status.

• α-Eudesmol Limits Ischemic Brain Injury via Cav2.1

  2026-08-28

  The reference study shows that α-eudesmol, an inhibitor of ω-agatoxin IVA-sensitive calcium channels, suppresses calcium-dependent glutamate release and reduces edema and infarction after focal cerebral ischemia in rats. Its value lies in connecting presynaptic P/Q-type channel pharmacology with acute ischemic neuroprotection, while also highlighting the selectivity limits of a small-molecule blocker.

• Decitabine Workflows for Cancer Epigenetics

  2026-08-27

  Decitabine enables controlled studies of DNMT1 inhibition, DNA hypomethylation, and tumor suppressor gene reactivation across hematologic and solid-tumor models. This workflow pairs dose–time design with molecular, phenotypic, and toxicity readouts so researchers can distinguish epigenetic priming from nonspecific cytotoxicity.

• In Situ TIL Therapy with Membrane-Anchored Anti-CD3

  2026-08-27

  The ACS Nano study introduces an in situ tumor-infiltrating lymphocyte strategy in which lipid nanoparticles deliver mRNA encoding a membrane-anchored anti-CD3 single-chain variable fragment to tumor-associated macrophages and tumor cells. This design combines local polyclonal T-cell activation with tumor-cell engagement and produces antitumor activity in B16F10 and MC38 models, including improved responses when paired with anti-PD-1 therapy.

• Ziprasidone Targets GOT1 in Pancreatic Cancer

  2026-08-26

  A 2022 Journal of Molecular Medicine study identified ziprasidone as a noncompetitive GOT1 inhibitor that disrupts glutamine metabolism, redox balance, and pancreatic ductal adenocarcinoma growth. Its combination of biochemical, cellular, genetic, metabolomic, and xenograft evidence supports GOT1 as a tractable metabolic target while leaving questions about selectivity and clinical translation unresolved.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-08-26

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suited to blunt-ended products for cloning and sequencing, but not to workflows that require 3′-A overhangs or sticky ends.

• HBsAg Targets TBK1 to Evade Innate Immunity

  2026-08-26

  This 2025 Cell Death and Disease study identifies a direct mechanism by which hepatitis B surface antigen redirects TBK1 signaling away from IRF3-dependent type I interferon production and toward incomplete autophagy. The findings connect HBsAg-driven TBK1 dimerization, p62 phosphorylation, and SNAP29 suppression with HBV persistence, providing a mechanistic framework for studying viral immune evasion.

• Cy3 TSA Fluorescence System Kit for Spatial Biology

  2026-08-25

  Discover how the Cy3 TSA Fluorescence System Kit converts pathway-level cancer biology into high-sensitivity spatial evidence. This article links tyramide signal amplification to the miR-3180–SCD1–CD36 findings in hepatocellular carcinoma while clarifying controls, assay boundaries, and interpretation.

• SM-102 LNP Workflow for mRNA Delivery

  2026-08-24

  Build a more disciplined SM-102 lipid nanoparticle workflow with practical starting conditions, orthogonal quality checks, and troubleshooting logic. The approach combines bench screening with machine-learning insights while keeping claims tied to formulation context rather than assuming one ionizable lipid will outperform in every assay.

• MLN2238: Proteasome β5 Inhibition Workflows

  2026-08-24

  Build more informative proteasome-inhibition assays with MLN2238, combining nanomolar β5-site activity with pathway-level measurements of apoptosis, ROS, JNK, and CREB. Practical guidance covers solubility, dose selection, resistance models, and translation of Drosophila stress-response findings into mammalian workflows.

7884 records 1/526 page Next 12345 下5页 Last page